- Home
- LTC vs ZYME Comparison
LTC vs ZYME Comparison
Compare LTC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LTC | ZYME |
|---|---|---|
| Founded | 1992 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 1994 | 2022 |
Fundamental Metrics
Financial Performance| Metric | LTC | ZYME |
|---|---|---|
| Price | $39.50 | $23.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $40.00 | $38.90 |
| AVG Volume (30 Days) | ★ 568.1K | 383.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.96% | N/A |
| EPS Growth | 23.53 | ★ 33.33 |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $262,854,000.00 | $105,965,000.00 |
| Revenue This Year | N/A | $183.10 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $37.60 | ★ N/A |
| Revenue Growth | 25.26 | ★ 38.87 |
| 52 Week Low | $33.64 | $13.06 |
| 52 Week High | $43.00 | $29.75 |
Technical Indicators
Market Signals| Indicator | LTC | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 52.20 |
| Support Level | $37.82 | $22.10 |
| Resistance Level | $39.65 | $26.92 |
| Average True Range (ATR) | 0.91 | 0.98 |
| MACD | -0.34 | 0.13 |
| Stochastic Oscillator | 32.34 | 72.07 |
Price Performance
Historical ComparisonAbout LTC LTC Properties Inc.
LTC Properties Inc is a real estate investment trust. It invests in seniors housing and health care properties, mainly through ownership, sale-leasebacks, mortgage financing, joint ventures, construction financing, and structured finance solutions, including preferred equity, bridge, and mezzanine lending. The company's investment portfolio comprises several properties located throughout the USA, the majority of which are seniors housing and skilled nursing properties. The firm conducts and manages its business as two operating segments: Real Estate Investments, which generates maximum revenue, and SHOP.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.